Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is expected to be posting its quarterly earnings results before the market opens on Friday, March 21st. Analysts expect Moleculin Biotech to post earnings of ($1.25) per share for the quarter.

Moleculin Biotech Trading Up 4.8 %

MBRX traded up $0.05 during trading hours on Thursday, hitting $1.09. The company’s stock had a trading volume of 451,310 shares, compared to its average volume of 1,396,514. The business’s 50-day moving average price is $1.38 and its 200-day moving average price is $2.04. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $7.80.

Analyst Ratings Changes

A number of research analysts have weighed in on MBRX shares. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Moleculin Biotech in a research report on Monday, March 3rd. StockNews.com assumed coverage on shares of Moleculin Biotech in a report on Thursday, March 13th. They set a “sell” rating on the stock. Finally, Maxim Group downgraded shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.